# Efficacy and safety of acupuncture in the treatment of chemotherapy-induced peripheral neuropathy in breast cancer patients: a systematic review and meta-analysis

**Authors:** Bozhen Huang, Meijiao Zhou, Shanshan Song, Siyi Ma, Min Jiang

PMC · DOI: 10.3389/fneur.2025.1690446 · Frontiers in Neurology · 2026-01-14

## TL;DR

This study finds that acupuncture can help reduce pain and improve outcomes for breast cancer patients with chemotherapy-induced nerve damage.

## Contribution

The paper provides a meta-analysis showing acupuncture's effectiveness for specific types of chemotherapy-induced neuropathy in breast cancer patients.

## Key findings

- Acupuncture improved clinical efficacy for taxane- and utidelone-induced neuropathy but not for unspecified agents.
- Acupuncture reduced pain intensity and improved FACT-NTX scores in breast cancer patients with CIPN.
- No significant benefits were observed for nerve conduction velocity, quality of life, or adverse reactions.

## Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect in breast cancer survivors. This meta-analysis evaluates the efficacy and safety of acupuncture for CIPN management.

We systematically searched PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang Database, VIP Database, and Chinese Biomedical Literature Database from database inception to August 3, 2025, for randomized controlled trials (RCTs) on acupuncture treatment for CIPN in breast cancer patients. We used RevMan 5.2 and Stata 16.0 for meta-analysis.

A total of 10 RCTs involving 653 patients were included. Treatment group significantly improved the clinical efficacy versus control group (RD = 0.22, 95% CI: 0.10, 0.33; p < 0.001). Chemotherapeutic agent subgroup analysis showed that acupuncture was beneficial for taxane-induced CIPN (RD = 0.26, 95% CI: 0.14, 0.38; p < 0.001) and utidelone-induced CIPN (RD = 0.33, 95% CI: 0.10, 0.56; p = 0.004), while the effect for CIPN from unspecified agents was not statistically significant (RD = 0.11, 95% CI: −0.20, 0.43; p = 0.484). The observed efficacy ranking was: utidelone-induced CIPN > taxane-induced CIPN > CIPN from unspecified agents. Acupuncture also reduced pain intensity (SMD = −0.65, 95% CI: −1.01, −0.29; p < 0.001) and FACT-NTX (WMD = 3.66, 95% CI: 1.00, 6.32; p = 0.007). No significant differences were found for peroneal nerve conduction velocity (WMD = 1.07, 95% CI: −4.25, 6.39; p = 0.694), quality of life score (SMD = 0.54, 95% CI: −0.20, 1.27; p = 0.153), or incidence of adverse reactions (RD = 0.03, 95% CI: −0.07, 0.13; p = 0.540).

In breast cancer patients with CIPN, acupuncture improved clinical efficacy, reduced pain intensity, and enhanced FACT-NTX scores, particularly in utidelone- and taxane-related cases. No clear benefits were seen for nerve conduction velocity, quality of life score, or incidence of adverse reactions. These findings support acupuncture as a safe and effective adjunct for CIPN symptom management in breast cancer patients.

https://www.crd.york.ac.uk/, identifier [CRD42024615214].

## Linked entities

- **Chemicals:** taxane (PubChem CID 9548828), utidelone (PubChem CID 447865)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Diseases:** breast cancer (MESH:D001943), pain (MESH:D010146), CIPN (MESH:D010523)
- **Chemicals:** utidelone (-), taxane (MESH:C080625)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12847451/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12847451/full.md

## References

44 references — full list in the complete paper: https://tomesphere.com/paper/PMC12847451/full.md

---
Source: https://tomesphere.com/paper/PMC12847451